Sol-Gel Technologies (NASDAQ:SLGL) & Iterum Therapeutics (NASDAQ:ITRM) Head to Head ReviewDefense World · 5 days ago
Sol-Gel Technologies (NASDAQ:SLGL) Stock Keeps “Buy” Rating at HC WainwrightDefense World · 5 days ago
Head to Head Analysis: Sol-Gel Technologies (NASDAQ:SLGL) vs. Trulieve Cannabis (NYSE:TRLV)Defense World · Oct 18, 2026
New Strong Buy Stocks for October 16thZacks Investment Research · Oct 16, 2026
Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome DataMarketBeat · Oct 14, 2026
Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day TranscriptSeeking Alpha · Oct 14, 2026Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 20, 2026 | -$2.36 | -$1.13 | Beat |
| May 28, 2026 | -$2.86 | -$1.31 | Beat |
| Mar 19, 2026 | $0.39 | -$1.07 | Miss |
| Nov 20, 2025 | -$2.09 | -$2.13 | Miss |
| Aug 15, 2025 | -$0.67 | $4.17 | Beat |
| May 19, 2025 | -$1.25 | -$3.20 | Miss |